Researchers have identified two potential therapeutic strategies for triple-negative breast cancer (TNBC), a highly aggressive form of the disease with limited treatment options.
miR-342 and the E2F Pathway: A New Therapeutic Target
A study published in EMBO Molecular Medicine identified miR-342 as a critical regulator of TNBC metastasis. The team found that low miR-342 levels correlated with poorer survival in TNBC patients, and restoring the microRNA significantly reduced metastatic growth in mouse models and human cell lines. The research, published in EMBO Molecular Medicine, revealed that miR-342 suppresses the E2F pathway, a key driver of cell proliferation and metastasis. By targeting this pathway, either through miR-342 restoration or the existing drug palbociclib, the team demonstrated a potential strategy to halt cancer spread. However, palbociclib has not yet been tested in TNBC patients, and further clinical trials are needed to validate these findings.
The findings highlight the importance of miR-342 as a biomarker for identifying TNBC patients who might benefit from E2F pathway inhibition.
DP103 as a Biomarker for Personalized TNBC Treatment
Researchers at the National University of Singapore’s Yong Loo Lin School of Medicine discovered that a protein called DP103 acts as a “master switch” driving TNBC growth and resistance to therapy. The study, published in Cell Death and Disease, also found that DP103 could serve as a biomarker to identify patients most likely to benefit from RX-5902, enabling a more personalized approach to treatment.
DP103 could potentially serve as a diagnostic biomarker to identify the patients most likely to benefit from RX-5902 treatment, paving the way for a more precise, personalised approach to treating triple-negative breast cancer,
said Alan Prem Kumar, an assistant professor at NUS Medicine. The team is now validating DP103 as a predictive biomarker in larger patient cohorts and exploring combinations with existing therapies to improve outcomes.
The Role of the PI3K Pathway in TNBC and Emerging Therapies
A review article outlined the complex role of the PI3K pathway in TNBC, noting its frequent activation through overexpressed or mutated receptor tyrosine kinases like IGF-1R and EGFR. The study highlighted the potential of monoclonal antibodies targeting PI3K-related pathways, such as Bavituximab, which targets phosphatidylserine, a molecule associated with the activation of PI3K/Akt signaling pathways. While direct PI3K-targeting antibodies remain limited, the article emphasized the importance of combining these approaches with existing therapies to address TNBC’s molecular diversity.
The study underscored the need for multi-pronged strategies, including immune checkpoint inhibitors and PI3K pathway modulation, to overcome resistance and improve survival.
What Comes Next: Translating Research into Clinical Practice
While these discoveries offer hope, significant hurdles remain. The miR-342-E2F strategy requires further clinical testing, particularly for palbociclib in TNBC patients. Similarly, RX-5902’s effectiveness in human trials is yet to be confirmed, and the PI3K pathway’s complexity demands more research into combination therapies.
As the field moves forward, the focus will remain on translating these laboratory breakthroughs into therapies that can improve outcomes for TNBC patients.
